Drug Profile
KF 17329
Latest Information Update: 28 May 2001
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Class Neuroprotectants; Nootropics; Quinoxalines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 28 May 2001 Discontinued-Preclinical for Cognition disorders in Japan (Unknown route)
- 19 Dec 1994 No-Development-Reported for Cognition disorders in Japan (Unknown route)